Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul 14:3:215-26.

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes

Joshua J Neumiller  1 , Travis E Sonnett, Lindy D Wood, Stephen M Setter, R Keith Campbell
Affiliations

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes

Joshua J Neumiller et al. Diabetes Metab Syndr Obes. .

Abstract

Liraglutide is a glucagon-like peptide-1 analog with pharmacokinetic properties suitable for once-daily administration approved by the Food and Drug Administration for the treatment of patients with type 2 diabetes. Clinical trial data from large, controlled studies demonstrate the safety and efficacy of liraglutide in terms of hemoglobin A(1c) (HbA(1c)) reduction, reductions in body weight, and the drug's low risk for hypoglycemic events when used as monotherapy. Liraglutide has been studied as monotherapy and in combination with metformin, glimepiride, and rosiglitazone for the treatment of type 2 diabetes. Additionally, comparative data with insulin glargine and exenatide therapy are available from Phase III trials. Once-daily administration may provide a therapeutic advantage for liraglutide over twice-daily exenatide, with similar improvements in HbA(1c) and body weight observed when liraglutide was compared with exenatide. The glucose-dependent mechanism of insulin release with incretin analog therapy holds potential clinical significance in the management of postprandial hyperglycemic excursions, with minimal risk of hypoglycemia when used with non-secretagogue medications. Data to date on patient-reported outcomes with liraglutide treatment are encouraging. The most common adverse events associated with liraglutide therapy are dose-dependent nausea, vomiting, and diarrhea. Diligent postmarketing surveillance to elucidate the risk of pancreatitis and medullary thyroid carcinoma in a heterogeneous population are likely warranted.

Keywords: diabetes; incretin analog; incretin effect; liraglutide.

PubMed Disclaimer

References

    1. World Health Organization. Diabetes Fact Sheet. [Accessed Dec 29, 2009]. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/index.html.
    1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2008.
    1. Ong KL, Cheung BM, Wong LY, et al. Prevalence, treatment and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999–2004. Ann Epidemiol. 2008;18:222–229. - PubMed
    1. Resnick HE, Foster GL, Bardsley J, et al. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999–2002: The National Health and Nutrition Examination Survey. Diabetes Care. 2006;29:531–537. - PubMed
    1. Turner RC, Cull CA, Frighi V, et al. UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 1 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49) JAMA. 1999;281:2005–2012. - PubMed

LinkOut - more resources